medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2010, Number 4

<< Back Next >>

Arch Neurocien 2010; 15 (4)

Identification of risk factors associated with ventriculoperitoneal shunts in patients with hydrocephalus secondary to cerebral cysticercosis

Ramos-Peek MA, Millán-Narváez VD, García-Navarrete R

Language: Spanish
References: 16
Page: 224-232
PDF size: 154.64 Kb.


ABSTRACT

Cerebral cysticercosis is a parasitic disease prevalent throughout the world, the symptoms are variable, and cephalic convolutions are frequent. If hydrocephalus is present the treatment is a shunt that may cease to work if obstructed. We studied 72 patients with hydrocephalus secondary to cisticercosis to which a ventriculoperitoneal shunt was applied. If there is a buildup of excess protein in the CSF, the extra protein will slowly clog the valve. The shunt can also become blocked at the distal end due most frequently to high pressure or from similar protein buildup.


REFERENCES

  1. Del Bigio MR. Pathophysiologic consecuences of hydrocephalus. Neurosurg Clin N Am 2001; 12(4):639-49.

  2. Pattisapu JV. Etiology and clinical course of hidrocephalus. Neurosurg Clin N Am 2001;12(4):651-9.

  3. Lo P, Drake JM. Shunt malfunctions. Neurosurg Clin N Am 2001;12(4):695-701, viii.

  4. Sotelo J, Arriada N, Lopez MA. Ventriculoperitoneal shunt of continuous flow vs valvular shunt for treatment of hydrocephalus in adults. Surg Neurol 2005;63(3):197-203.

  5. Lund-Johansen M, Svendsen F, Wester K. Shunt failures and complications in adults as related to shunt type, diagnosis, and the experience of the surgeon. Neurosurgery 1994;35(5):839-44.

  6. Kelley R, Duong DH, Locke GE. Characteristics of ventricular shunt malfunctions among patients with neurocysticercosis. Neurosurgery 2002;50(4):757-61; discussion 761-2.

  7. Colli BO, Martelli N, Assirati JA Jr, Machado HR, de Vergueiro Forjaz S. Results of surgical treatment of neurocysticercosis in 69 cases. J Neurosurg 1986;65(3):309-15.

  8. Weng X, Shi Y, Pan X, Mo L. CSF-VP shunt placement and albendazole therapy for cerebral cisticercosis. Chinese Med J 2002;115(6):936-8.

  9. Proaño JV, Madrazo I, Avelar F, Lopez-Felix B, Diaz G, Grijalva I. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med 2001;345(12):879-85.

  10. Suastegui Roman RA, Soto-Hernandez JL, Sotelo J. Effects of prednisone on ventriculoperitoneal shunt function in hydrocephalus secondary to cysticercosis: a preliminary study. J Neurosurg 1996;84(4):629-33.

  11. Villavicencio AT, Leveque JC, McGirt MJ, Hopkins JS, Fuchs HE, George TM. Comparison of revision rates following endoscopically versus nonendoscopically placed ventricular shunt catheters. Surg Neurol 2003;59(5):375-9; discussion 379-80.

  12. Kestle JR, Drake JM, Cochrane DD, Milner R, Walker ML, Abbott R 3rd, Boop FA Lack of benefit of endoscopic ventriculoperitoneal shunt insertion: amulticenter randomized trial. J Neurosurg 2003; 98(2):284-90.

  13. Snow RB, Kossovsky N. Hypersensitivity reaction associated with sterile ventriculoperitoneal shunt malfunction. Surg Neurol 1989; 31(3):209-14.

  14. Djientcheu VD, Zona G, Rilliet B. Neurocysticercosis: migration and proliferation of cysticercus in a CSF valve. Br J Neurosurgery 2000;14(2):135-7.




2020     |     www.medigraphic.com